[Translated article] Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD.

[1]  M. Miravitlles,et al.  Results of a Diagnostic Procedure Based on Multiplex Technology on Dried Blood Spots and Buccal Swabs for Subjects With Suspected Alpha1 Antitrypsin Deficiency , 2021, Archivos de Bronconeumología (English Edition).

[2]  M. Miravitlles,et al.  GesEPOC 2021: One More Step Towards Personalized Treatment of COPD , 2021, Archivos de Bronconeumología (English Edition).

[3]  F. Martinez,et al.  Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease , 2020, American journal of respiratory and critical care medicine.

[4]  Luis Jara-Palomares,et al.  Documento de consenso de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) para el seguimiento clínico post-COVID-19 , 2020, Open Respiratory Archives.

[5]  N. Papadopoulos,et al.  Face masks, respiratory patients and COVID-19 , 2020, European Respiratory Journal.

[6]  M. Miravitlles,et al.  GesEPOC 2021: One More Step Towards Personalized Treatment of COPD. , 2020, Archivos de bronconeumologia.

[7]  M. Miravitlles,et al.  A Proposed Approach to Chronic Airway Disease (CAD) Using Therapeutic Goals and Treatable Traits: A Look to the Future , 2020, International journal of chronic obstructive pulmonary disease.

[8]  M. Miravitlles,et al.  The Importance of Reference Centers and Registries for Rare Diseases: The Example of Alpha-1 Antitrypsin Deficiency , 2020, COPD.

[9]  M. Miravitlles,et al.  Prevalence of α1-antitrypsin PiZZ genotypes in patients with COPD in Europe: a systematic review , 2020, European Respiratory Review.

[10]  D. Price,et al.  Changes in Control Status of COPD Over Time and Their Consequences: A Prospective International Study. , 2020, Archivos de bronconeumologia.

[11]  M. Miravitlles,et al.  Results of a Diagnostic Procedure Based on Multiplex Technology on Dried Blood Spots and Buccal Swabs for Subjects With Suspected Alpha1 Antitrypsin Deficiency. , 2020, Archivos de bronconeumologia.

[12]  P. Dorinsky,et al.  Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. , 2020, The New England journal of medicine.

[13]  M. Martínez-García,et al.  Consensus Document on the Diagnosis and Treatment of Chronic Bronchial Infection in Chronic Obstructive Pulmonary Disease. , 2020, Archivos de bronconeumologia.

[14]  S. Aaron,et al.  Dual LABA/LAMA Therapy versus LABA or LAMA Monotherapy for COPD: A Systematic Review and Meta-analysis in Support of the American Thoracic Society Clinical Practice Guideline. , 2020, Annals of the American Thoracic Society.

[15]  M. Miravitlles,et al.  Current Challenges in Chronic Bronchial Infection in Patients with Chronic Obstructive Pulmonary Disease , 2020, Journal of clinical medicine.

[16]  Jesús Molina París,et al.  Seguimiento del paciente con enfermedad respiratoria en la era post-COVID-19: ¿estamos preparados? , 2020, Archivos de Bronconeumología.

[17]  M. Miravitlles,et al.  The right treatment for the right patient with COPD: lessons from the IMPACT trial , 2020, European Respiratory Journal.

[18]  J. Wedzicha,et al.  Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline , 2020, American journal of respiratory and critical care medicine.

[19]  D. Price,et al.  Predictive value of control of COPD for risk of exacerbations: An international, prospective study , 2020, Respirology.

[20]  A. Aldhahir,et al.  Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis , 2020, medRxiv.

[21]  G. Lippi,et al.  Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19) , 2020, Respiratory Medicine.

[22]  J. Curtis,et al.  Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease , 2020, American journal of respiratory and critical care medicine.

[23]  M. Miravitlles,et al.  Spanish Implementation of the New International Alpha-1 Anitrypsin Deficiency International Registry: The European Alpha-1 Research Collaboration (EARCO). , 2020, Archivos de bronconeumologia.

[24]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[25]  M. Miravitlles,et al.  Blood Eosinophil Counts and Their Variability and Risk of Exacerbations in COPD: A Population-Based Study. , 2020, Archivos de bronconeumologia.

[26]  J. López-Campos,et al.  The Clinical Implications of Triple Therapy in Fixed-Dose Combination in COPD: From the Trial to the Patient. , 2020, Archivos de bronconeumologia.

[27]  C. E. Santaolalla,et al.  Ventilación mecánica a domicilio , 2016, Open Respiratory Archives.

[28]  M. Miravitlles,et al.  Clinical Control in COPD: A New Therapeutic Objective? , 2020, Archivos de Bronconeumologia.

[29]  M. Miravitlles,et al.  Clinical Characteristics and Risk of Exacerbations Associated With Different Diagnostic Criteria of Asthma-COPD Overlap. , 2019 .

[30]  J. Soriano,et al.  Adjusting the Level of Intervention in Patients with Chronic Obstructive Pulmonary Disease According to the Risk Stratification Proposed by the Spanish COPD Guidelines (GesEPOC) Version 2017. , 2019 .

[31]  R. Golpe,et al.  Plasma Eosinophil Count and Patient-Centered Events in Chronic Obstructive Pulmonary Disease in Real-Life Clinical Practice. , 2019 .

[32]  E. Kerwin,et al.  Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial , 2019, Respiratory Research.

[33]  C. Montón,et al.  Nebulized Colistin And Continuous Cyclic Azithromycin In Severe COPD Patients With Chronic Bronchial Infection Due To Pseudomonas aeruginosa: A Retrospective Cohort Study , 2019, International journal of chronic obstructive pulmonary disease.

[34]  Meilan K. Han,et al.  Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. , 2019, The Lancet. Respiratory medicine.

[35]  B. Celli,et al.  Prognostic Validation Using GesEPOC 2017 Severity Criteria. , 2019, Archivos de bronconeumologia.

[36]  N. Zhong,et al.  Tiotropium discontinuation in patients with early-stage COPD: a prospective observational cohort study , 2019, ERJ Open Research.

[37]  J. Soriano,et al.  ACO: Time to move from the description of different phenotypes to the treatable traits , 2019, PloS one.

[38]  R. Golpe,et al.  Should Lung Function Be Included in the Risk Stratification of Chronic Obstructive Pulmonary Disease Proposed by GesEPOC? , 2019, Archivos de bronconeumologia.

[39]  F. Martinez,et al.  Pulmonary hypertension in chronic lung disease and hypoxia , 2019, European Respiratory Journal.

[40]  B. Celli,et al.  Prognostic Validation Using GesEPOC 2017 Severity Criteria. , 2019, Archivos de bronconeumologia.

[41]  M. Miravitlles,et al.  Validation of clinical control in COPD as a new tool for optimizing treatment , 2018, International journal of chronic obstructive pulmonary disease.

[42]  S. Suissa,et al.  Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. , 2018, The Lancet. Respiratory medicine.

[43]  M. Miravitlles,et al.  Recommendations on non-Pharmacological Treatment in Chronic Obstructive Pulmonary Disease From the Spanish COPD Guidelines (GesEPOC 2017). , 2018, Archivos de bronconeumologia.

[44]  F. Venuta,et al.  Bronchoscopic treatment of emphysema: an update. , 2018, Journal of thoracic disease.

[45]  A. Morice,et al.  Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial , 2018, JAMA.

[46]  M. Humbert,et al.  Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype? , 2018, American journal of respiratory and critical care medicine.

[47]  A. Anzueto,et al.  The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD. , 2018, The American journal of medicine.

[48]  J. Wedzicha,et al.  Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. , 2018, The Lancet. Respiratory medicine.

[49]  C. Montón,et al.  Clinical and Safety Outcomes of Long‐Term Azithromycin Therapy in Severe COPD Beyond the First Year of Treatment , 2018, Chest.

[50]  Meilan K. Han,et al.  Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPD , 2018, The New England journal of medicine.

[51]  J. Barberà,et al.  Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Summary of Recommendations. , 2018 .

[52]  N. Roche,et al.  Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial , 2018, The Lancet.

[53]  C. Olveira,et al.  Spanish Guidelines on Treatment of Bronchiectasis in Adults. , 2017, Archivos de bronconeumologia.

[54]  M. Miravitlles,et al.  Accuracy of a New Algorithm to Identify Asthma-COPD Overlap (ACO) Patients in a Cohort of Patients with Chronic Obstructive Airway Disease. , 2017, Archivos de bronconeumologia.

[55]  J. Soriano,et al.  Asthma-COPD overlap is not a homogeneous disorder: further supporting data , 2017, Respiratory Research.

[56]  A. Dirksen,et al.  European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency , 2017, European Respiratory Journal.

[57]  J. Soriano,et al.  Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD , 2017, European Respiratory Journal.

[58]  J. Wedzicha,et al.  Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline , 2017, European Respiratory Journal.

[59]  J. Soriano,et al.  Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase. , 2017, Archivos de bronconeumologia.

[60]  M. Miravitlles,et al.  Bronchiectasis in COPD patients: more than a comorbidity? , 2017, International journal of chronic obstructive pulmonary disease.

[61]  J. Soriano,et al.  Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study , 2017, International journal of chronic obstructive pulmonary disease.

[62]  M. Miravitlles,et al.  Consensus on the Asthma-COPD Overlap Syndrome (ACOS) Between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA). , 2017, Archivos de bronconeumologia.

[63]  Dave Singh,et al.  Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial , 2016, The Lancet.

[64]  K. Rabe,et al.  Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. , 2016, American journal of respiratory and critical care medicine.

[65]  I. Pavord,et al.  Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. , 2016, The Lancet. Respiratory medicine.

[66]  J. Curtis,et al.  Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. , 2016, Annals of the American Thoracic Society.

[67]  R. Rodríguez-Roisín,et al.  Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial. , 2016, Chest.

[68]  J. Wedzicha,et al.  Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. , 2016, The New England journal of medicine.

[69]  M. Cazzola,et al.  A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. , 2016, Chest.

[70]  Dave Singh,et al.  Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials. , 2016, Respiratory medicine.

[71]  I. Pavord,et al.  Treatable traits: toward precision medicine of chronic airway diseases , 2016, European Respiratory Journal.

[72]  J. Soriano,et al.  Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort. , 2016, Chest.

[73]  I. Pavord,et al.  Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD , 2015, Thorax.

[74]  Berend C Stoel,et al.  Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[75]  S. Johnston,et al.  Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. , 2014, The Lancet. Respiratory medicine.

[76]  Jeffrey R Stout,et al.  Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS) , 2014, Age and ageing.

[77]  L. Raiteri,et al.  Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD. , 2014, Chest.

[78]  Stefano Nava,et al.  Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. , 2014, The Lancet. Respiratory medicine.

[79]  H. Hoogsteden,et al.  Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. , 2014, The Lancet. Respiratory medicine.

[80]  L. Raiteri,et al.  Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. , 2014, The Lancet. Respiratory medicine.

[81]  L. Puente Maestu,et al.  Continuous home oxygen therapy. , 2014, Archivos de bronconeumologia.

[82]  M. Decramer,et al.  Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. , 2013, The Lancet. Respiratory medicine.

[83]  M. Miravitlles,et al.  Quality and strength: the GRADE system for formulating recommendations in clinical practice guidelines. , 2013, Archivos de bronconeumologia.

[84]  J. Wedzicha,et al.  Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. , 2013, The Lancet. Respiratory medicine.

[85]  M. Martínez-García,et al.  Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[86]  Eman O. Arram,et al.  Bronchiectasis in COPD patients , 2012 .

[87]  Wu Guo-cheng,et al.  Prevention of COPD Exacerbations , 2012 .

[88]  J. Soriano,et al.  Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. , 2012, Archivos de bronconeumologia.

[89]  John Connett,et al.  Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[90]  Joan B Soriano,et al.  Overdiagnosing subjects with COPD using the 0.7 fixed ratio: correlation with a poor health-related quality of life. , 2011, Chest.

[91]  K. Rabe,et al.  Tiotropium versus salmeterol for the prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[92]  D. D. Briggs,et al.  Evaluation of withdrawal of maintenance tiotropium in COPD. , 2009, Respiratory medicine.

[93]  F. Martinez,et al.  Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials , 2009, The Lancet.

[94]  Lucas M Bachmann,et al.  Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis , 2009, BMC Medicine.

[95]  N. Zhong,et al.  Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study , 2008, The Lancet.

[96]  J. E. Hansen,et al.  Spirometric criteria for airway obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not < 70%. , 2007, Chest.

[97]  N. Zhong,et al.  Positive benefits of theophylline in a randomized, double‐blind, parallel‐group, placebo‐controlled study of low‐dose, slow‐release theophylline in the treatment of COPD for 1 year , 2006, Respirology.

[98]  Y. Lacasse,et al.  Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. , 2005, Respiratory medicine.

[99]  C. Cooper,et al.  The role of long-acting bronchodilators in the management of stable COPD. , 2004, Chest.

[100]  F. Ram,et al.  Short-acting beta2-agonists for stable chronic obstructive pulmonary disease , 2002 .

[101]  R. Zuwallack,et al.  Salmeterol plus theophylline combination therapy in the treatment of COPD. , 2001, Chest.

[102]  J. Escarrabill,et al.  Ventilación mecánica a domicilio , 1990 .